IN3 Europe Banner

Implantable Weight-Loss Device Receives CE Mark Approval

Many patients who struggle with obesity consider gastric bypass surgery as an option for managing their weight. Procedures such as stomach stapling or lap-band surgery can help patients lose significant amounts of weight and improve the symptoms of obesity-related conditions like Type 2 diabetes. However,...

Resverlogix to Begin Phase II Atherosclerosis Trial

Canadian biopharmaceutical company Resverlogix has commenced a Phase II clinical trial for RVX-208, its small molecule therapy for the treatment of atherosclerosis in patients with stable coronary artery disease. The Cleveland Clinic was the first medical center to begin dosing patients in the ASSERT (ApoA1...

Researchers Identify Gene Linked to Childhood Asthma

U.S. researchers have identified a gene that is linked to childhood asthma. The discovery may one day lead to new treatments for this debilitating disease, which affects 9 million children in the U.S. The study, published in the Jan. 7 issue of the New England Journal of Medicine, compared the genetics of...

Clarient Acquires AGI In All-Stock Merger

Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Huntsville, Ala.-based Applied Genomics in an all-stock merger worth up to $17.6 million. The agreement will give Clarient access to the rapidly increasing epidermal growth factor receptor (EGFR) testing...

New Era Begins for NeoStem Following China Acquisition

By Mike Havrilla, ProActive News Room NeoStem (AMEX: NBS) [click on preceding link for the Company' s News Room website] is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications that is...

Ambit and Astellas Sign $350M Development Deal

Ambit Biosciences has entered into a $390 million agreement with Japan’s Astellas Pharma to develop and commercialize FLT3 kinase inhibitors to treat cancer and other conditions. The deal will include Ambit’s AC220, a kinase inhibitor currently in Phase II trials to treat a form of blood cancer...

Possible Cause of Inflammatory Bowel Disease Uncovered

An Australian scientist has discovered a possible cause of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.  A researcher at the University of Adelaide found that people suffering from inflammatory bowel disease have a lower number of regulatory cells that control the immune...